LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ahead. Explore more here.

From there, the case for or against investing in Lilly should become much clearer. Eli Lilly's earnings report

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE). When the COVID-19 pandemic began in 2020, Pfizer quickly emerged as the leader in the race to develop a vaccine.

Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.